The study was designed to qualitative and quantitative evaluation of the antinociceptive effect of metoclopramide and xylazine each alone or as a concomitant administration in mice. Adult albino Swiss mice weighing 20-30 mg used in all experiments. By using the hot plate test, the individual analgesic dose (ED50) of metoclopramide and xylazine detected depending on the up and down method. Isobolographic analysis used to evaluate the type of interaction between two drugs at the ratio 0.5:0.5 of individual ED50 for each drug at the level of antinociception effect. Simultaneously administration of the double dose of individual ED50 and low doses (sedative, non-analgesic doses) of both drugs, also evaluated at the level of central and visceral analgesia using a hot plate and writhing response test respectively. The individual ED50 of xylazine and metoclopramide was 10.8 and 25.6mg/kg IP respectively. A synergistic interaction at the level of analgesia explored between two drugs at ratio 0.5:0.5 which represented as decreased in ED50 of metoclopramide and xylazine by 58.75 and 58.15% respectively. The animal suffered from only slight sedation and docile. Simultaneously IP administration of xylazine and metoclopramide at double dose of ED50 for each drug-induced significant increase in latency time of thermal response, as well as a significant decrease in writhes number, which induced by acetic acid in comparison with control groups. The percentage of analgesia at sub analgesic doses of a concomitant administration of both drugs was 100% in comparison with each drug alone. These results suggested safe and good use of both drugs in veterinary medicine.

The study aimed to explore the ameliorative effects of silymarin when administered with flunixin on the liver, kidney, and blood components in rats. The animals were divided into four groups; each one consists of five rats. The first group was served as a control. The second and third groups were treated with silymarin 200 mg/kg b.wt, p.o and flunixin 2.5 mg/kg b.wt, i.p respectively. The fourth group was treated with silymarin and flunixin concurrently. The involved rats were treated for seven consecutive days by a single daily dose. Following the treatment, the biochemical analysis ALT, AST, ALP, Urea, and Creatinine, blood analysis parameters RBC, HGB, HCT, WBC, and PLT, and a histopathological examination liver and kidney were studied for the involved animals. The results showed that flunixin increased the levels of ALT and AST and the concentrations of Urea and Creatinine, and the total number of WBC. Also silymarin caused a remarkable decrease in the flunixin adverse effects on the liver and kidneys. This was reflected from the histological features observed from the diverse tested groups. Based on these findings, the authors concluded that silymarin has the ability to reduce the harmful effects of flunixin on both the liver and the kidneys.

No abstract

Background and objectives: hyperlipidemia is the hallmark of cardiovascular diseases, namely hypertension, ischemic heart diseases, and strokes. Treatment should be satisfactory to tackle the lipid disorder and maintain the circulatory normal lipid profile. Many factors/cofactors coordinate to maintain lipid levels within normal to avoid subsequent hazards associated with hyperlipidemia. Coenzyme Q10 is a ubiquitous endogenous biomolecule that plays an important biological role in the lipid catabolic pathway. The goal of the study is to define the role of Coenzyme Q10 in hyperlipidemic mice model induced manually.Methods: to do so, a diet based hyperlipidemia state was induced in mice and they were distributed into different groups to conform with our study objectives. A Coenzyme Q10 treated group was compared to the negative control group and the positive control group was used as well.Results: The biochemical and histological outcomes declared that Coenzyme Q10 has important lipidreducing effects which are parallel or even superior to lipid reducing drugs (e.g. Rosuvastatin). Conclusion of the present study addressed the lipid-lowering properties of Coenzyme Q10 in a newly induced hyperlipidemia mouse model bestowing the use of Coenzyme Q10 as add-on adjuvant therapy in a high-risk group or as a monotherapy in a prophylactic group.